Scarica l'app Stockscreener
54.69
4.21%
2.21
Precedente Chiudi:
$52.48
Aprire:
$52.72
Volume 24 ore:
3.00M
Relative Volume:
1.32
Capitalizzazione di mercato:
$10.51B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
20.33
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-0.07%
1M Prestazione:
+1.64%
6M Prestazione:
-6.48%
1 anno Prestazione:
-13.81%
Intervallo 1D:
$52.51
$54.76
Intervallo di 1 settimana:
$51.99
$55.24
Portata 52W:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.69 | 10.08B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Finviz
Will BioMarin Pharmaceutical Inc. (BM8) stock beat revenue estimatesWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com
How BioMarin Pharmaceutical Inc. (BM8) stock responds to bond marketTrade Exit Report & Weekly High Conviction Trade Ideas - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peersMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Will BioMarin Pharmaceutical Inc. (BM8) stock attract long term capital inflowsJuly 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap vs fundamentalsCEO Change & AI Enhanced Market Trend Forecasts - newser.com
How higher bond yields impact BioMarin Pharmaceutical Inc. (BM8) stock2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecasts2025 Key Lessons & Fast Gain Stock Tips - newser.com
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Will BioMarin Pharmaceutical Inc. stock split attract more investors - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.CEO Change & Consistent Profit Trade Alerts - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for BioMarin Pharmaceutical Inc. stock2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Risk Controlled Swing Alerts - newser.com
How currency fluctuations impact BioMarin Pharmaceutical Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):